Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedLocations section reorganized to add California, Georgia, Massachusetts, Ohio, and Texas as locations and to remove the previous state blocks, with the page revision updated from v3.3.2 to v3.3.3.SummaryDifference0.6%

- Check24 days agoNo Change Detected
- Check45 days agoChange DetectedThe Publications section text was updated to clarify that entries are automatically filled from PubMed and may not pertain to the study; the revision/version label was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check52 days agoChange DetectedDeletion removes a general government funding/operating-status notice, while the Study Details content (title, conditions, plan, and eligibility) remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check74 days agoChange DetectedNo significant changes detected between the two screenshots; the page content and structure appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check95 days agoChange Detected- Added a government funding notice and current operating status information, plus a new version tag v3.2.0. - Removed the term 'Adrenal cortex carcinoma' and the older version tag v3.1.0.SummaryDifference2%

- Check102 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.